← Back to Search

Photosensitizer

PXL-Platinum 330 in Eyes With Corneal Thinning Conditions

Phase 1 & 2
Waitlist Available
Led By Vishal Jhanji, MD
Research Sponsored by Vishal Jhanji
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new way to treat corneal thinning disorders using UV light and a photosensitizer called riboflavin.

Eligible Conditions
  • Corneal Atrophy
  • Keratoconus

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
PXL-Platinum 330 system
Other study objectives
Efficacy measurements by best spectacle-corrected visual acuity

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Pulsed lightingExperimental Treatment1 Intervention
Group II: Continuous lightingExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Vishal JhanjiLead Sponsor
1 Previous Clinical Trials
Vishal Jhanji, MDPrincipal InvestigatorUPMC Eye Center
1 Previous Clinical Trials

Media Library

Peschke-TE 0.25% ophthalmic solution or Peschke-L 0.23% ophthalmic solution (Photosensitizer) Clinical Trial Eligibility Overview. Trial Name: NCT05489510 — Phase 1 & 2
Corneal Atrophy Research Study Groups: Pulsed lighting, Continuous lighting
Corneal Atrophy Clinical Trial 2023: Peschke-TE 0.25% ophthalmic solution or Peschke-L 0.23% ophthalmic solution Highlights & Side Effects. Trial Name: NCT05489510 — Phase 1 & 2
Peschke-TE 0.25% ophthalmic solution or Peschke-L 0.23% ophthalmic solution (Photosensitizer) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05489510 — Phase 1 & 2
~0 spots leftby Dec 2031